Published On : 2018-12-10
Hypoparathyroidism is state in which there is inadequate parathyroid hormone production in the patient’s body. The condition is rare and its common occurrence is due to the removal of parathyroid glands during thyroid or parathyroid surgeries. The condition of hyperparathyroidism involves a decreased activity or secretion of parathyroid hormones, which results in the lowered levels of calcium in the blood, also known as hypocalcemia, and increased level of phosphorus that is hyperphosphatemia.
New Data Illustrating Hypoparathyroidism Treatment Effects
The leading companies participating in the hypoparathyroidism treatment market are majorly focusing on exploring the possibilities to potentially innovate in the way hypoparathyroidism is treated with unique drug innovations and constant research on minimizing the complexities of this rare endocrine disorder.
Shire-NPS Pharmaceuticals, Inc. is amongst the key players in the hypoparathyroidism treatment market. The company has continued to be a leader in clinical domain of Hypoparathyroidism treatment with several active clinical trials in action. The company has reinforced the understanding of chronic hypoparathyroidism by showcasing necessary information regarding the new hypotheses about the long-term effects of hypoparathyroidism treatment along with notable information on efficacy and safety of the rhPTH (1-84) treatment alternative. Apart from this study that uncovers key insights, Shire presented several real-world and clinical studies. Such insightful data could prove beneficial for assisting physicians in boosting their understanding of hypoparathyroidism, thereby achieving improved outcomes. This data illustrates Shire’s continued commitment to make a difference in patient’s lives while they deal with rare diseases.
Advancements for Better Disease Management
With the severance and rarity of hypoparathyroidism, the need for better treatment and disease management is rising. The need for better disease management has triggered the advancement in clinical trials and research. Research and development plays a crucial role in reaching potential heights of treatment management.
The new study unveils that the delivering Parathyroid Hormone (PTH) 1-34 with the help of insulin pump aid in effective management of hypoparathyroidism, as the PTH 1-34 normalizes serum and urine calcium as well as the bone turnover markers. The delivery of PTH 1-34 also contributed to the production of stable magnesium values that lie within the expected range, reducing the excretion of magnesium. Such advancements highlight the effectiveness of this procedure for better hypoparathyroidism treatment and management. Continued research is expected to open new avenues of treatment for hypoparathyroidism in the forthcoming years.
Unveiling an All-new Feasible Hypoparathyroidism Treatment
In light of the on-going and continual developments towards achieving notable success in hypoparathyroidism treatment has triggered major innovations across the healthcare sector. The immense opportunities that are opening up post these revelations are beginning to drive the hypoparathyroidism treatment market growth. Korean researchers have gained success with new hypoparathyroidism treatment, where they examined the feasibility of autologous plasma gel for stem cells derived from tonsil, in the hypoparathyroidism treatment. According to the findings, plasma gel could be considered as a potential hypoparathyroidism treatment as it is solid scaffold material for delivering cells that produce and secrete PTH. Furthermore, it is indicated that the plasma gel is easily injectable, applicable to human, and a cell-friendly material, making it a highly feasible treatment model for treating patients suffering from hypoparathyroidism.
FDA Approvals to Foster Effective Therapeutics in Hypoparathyroidism
Approvals for use of drugs play a vital role in the treatment of diseases, as they act as a certification that allows the use of those drugs. Pharmaceutical companies are constantly focusing towards developing drugs that fit the regulatory requirements and obtain the approval of regulatory bodies.
The US Food and Drug Administration (FDA) granted the Orphan Drug Designation (ODD) to TransCon PTH, the long-acting prodrug for parathyroid hormone, developed by Ascendis Pharma, which was presently in development for hypoparathyroidism treatment. Such developments are expected to boost the hypoparathyroidism treatment on a large-scale, providing key opportunities to the hypoparathyroidism treatment market players.
The hypoparathyroidism treatment market research study encompasses the major elements that describe the overall market with respect to the present and future market scenario. The key findings, detailed insights, promising segments, and lucrative regions illustrated in the report showcase the potential opportunities offered by the hypoparathyroidism treatment market. To avail necessary information pertaining to the opportunities and industry trends, click here.